Adjuvant Chemotherapy for Non-Small Cell Lung Cancer

REFERENCES

• Jemal A., Siegel R., Ward E., et al. Cancer Statistics, 2006. CA Cancer J. Clin. 2006; 56(2)106–130
   PubMed Web of Science ®Google Scholar
• Parkin D. M., Bray F., Ferlay J., Pisani P. Global Cancer Statistics, 2002. CA Cancer J. Clin. 2005; 55(2)74
   PubMed Web of Science ®Google Scholar
• Mountain C. F. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111(6)1710–1717
   PubMed Web of Science ®Google Scholar
• Van Rens M. T.M., De la Riviere A. B., Elbers H. R.J., Van den Bosch J. M.M. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 2000; 117(2)374
   PubMed Web of Science ®Google Scholar
• Naruke T., Tsuchiya R., Kondo H., Asamura H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Annals of Thoracic Surgery 2001; 71(6)1759
   PubMed Web of Science ®Google Scholar
• Fang D., Zhang D., Huang G., Zhang R., Wang L., Zhang D. Results of surgical resection of patients with primary lung cancer: a retrospective analysis of 1,905 cases. Annals of Thoracic Surgery 2001; 72(4)1155
   PubMed Web of Science ®Google Scholar
• Goya T., Asamura H., Yoshimura H., et al. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 2005; 50: 2–227
   Google Scholar
• Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311(7010)899–909
   PubMed Web of Science ®Google Scholar
• Keller S. M., Adak S., Wagner H., et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N. Engl. J. Med. 2000; 343(17)1217–1222
   PubMed Web of Science ®Google Scholar
• PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998; 352(9124)257–263
   PubMed Web of Science ®Google Scholar
• Burdett S., Stewart L. Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis. Lung Cancer 2005; 47(1)81
   PubMed Web of Science ®Google Scholar
• Scagliotti G. V., Fossati R., Torri V., et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J. Natl. Cancer Inst. 2003; 95(19)1453–1461
   PubMed Web of Science ®Google Scholar
• Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J. P., Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. 2004; 350(4)351–360
   PubMed Web of Science ®Google Scholar
• Waller D., Peake M. D., Stephens R. J., et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur. J. Cardiothorac. Surg. 2004; 26(1)173–182
   PubMed Web of Science ®Google Scholar
• Winton T., Livingston R., Johnson D., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N. Engl. J. Med.; 2005; 352(25)2589–2597
   PubMed Web of Science ®Google Scholar
• Strauss G., Herndon J., Maddaus M. A., et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J. Clin. Oncol. 2004; 22: 7019, (Suppl. 14). ASCO Annual Meeting Proceedings (Post-Meeting Edition)
   Google Scholar
• Strauss G. M., Herndon J. E., Maddaus M. A., et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. J. Clin. Oncol. 2006; 24: 7007, (Suppl. 18S), No. 18S, 2006 ASCO Annual Meeting Proceedings Part I
   Google Scholar
• Douillard J., Rosell R., Delena M., Legroumellec A., Torres A., Carpagnano F. ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up.On behalf of the Adjuvant Navelbine International Trialist Association. Part I of II. J. Clin. Oncol. 2005; 23: 7013, (Suppl. 16), 2005 ASCO Annual Meeting Proceedings
   PubMed Web of Science ®Google Scholar
• Kato H., Ichinose Y., Ohta M., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N. Engl. J. Med. 2004; 350(17)1713–1721
   PubMed Web of Science ®Google Scholar
• Nakagawa M., Tanaka F., Tsubota N., et al. A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)—the 4th study. Ann. Oncol. 2005; 16(1)75–80
   PubMed Web of Science ®Google Scholar
• Wada H., Hitomi S., Teramatsu T. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J. Clin. Oncol. 1996; 14(4)1048–1054
   PubMed Web of Science ®Google Scholar
• Endo C., Saito Y., Iwanami H., et al. A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-East Japan Study Group for Lung Cancer Surgery. Lung Cancer 2003; 40: 2–181
   Google Scholar
• Tada H., Yasumitsu T., Iuchi K., Taki T., Komada K., Matsumura A. Randomized control study of adjuvant chemotherapy with UFT alone or plus cisplatin and vindesine in patients with completely resected non-small cell lung cancer. Lung Cancer 2003; 41(2)S54, 0–182
   Google Scholar
• Imaizumi M. A randomized trial of postoperative adjuvant chemotherapy for p-stage I non-small cell lung cancer (4th cooperative study). Lung Cancer 2003; 41(2)S54, 0–182
   Google Scholar
• Hamada C., Tanaka F., Ohta M., et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J. Clin. Oncol. 2005; 23(22)4999–5006
   PubMed Web of Science ®Google Scholar
• Hotta K., Matsuo K., Ueoka H., Kiura K., Tabata M., Tanimoto M. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J. Clin. Oncol. 2004; 22(19)3860–3867
   PubMed Web of Science ®Google Scholar
• Sedrakyan A., Van Der Meulen J., O'Byrne K., Prendiville J., Hill J., Treasure T. Postoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis. J. Thorac. Cardiovasc. Surg. 2004; 128(3)414–419
   PubMed Web of Science ®Google Scholar
• Berghmans T., Paesmans M., Meert A. P., et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 2005; 49(1)13–23
   PubMed Web of Science ®Google Scholar
• Pignon J. P., Tribodet H., Scagliotti G. V., et al. A pooled analysis of five randomized clinical trials including 4,584 patients. J. Clin. Oncol. 2006; 24: 7008, (Suppl. 18S). 2006 ASCO Annual Meeting Proceedings Part I
   Google Scholar
• Melo M. J., Barradas P., Costa A., Cristovao M., Alves P. Results of a randomized phase III trial comparing 4 cisplatin (P)-based regimens in the treatment of locally advanced and metastatic non-small cell lung cancer (NSCLC): mitomycin/vinblastine/cisplatin (MVP) is no longer a therapeutic option. Proc. Am. Soc. Clin. Oncol. 2002; 21, (Abstr. 1205)
   Google Scholar
• Rudd R. M., Gower N. H., Spiro S. G., et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J. Clin. Oncol. 2005; 23(1)142–153
   PubMed Web of Science ®Google Scholar
• Alberola V., Camps C., Provencio M., et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J. Clin. Oncol. 2003; 21(17)3207–3213
   PubMed Web of Science ®Google Scholar
• Souquet P. J., Tan E. H., Rodrigues Pereira J., et al. GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients. Ann. Oncol. 2002; 13(12)1853–1861
   PubMed Web of Science ®Google Scholar
• Scagliotti G. V., De Marinis F., Rinaldi M., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol. 2002; 20(21)4285–4291
   PubMed Web of Science ®Google Scholar
• Kelly K., Crowley J., Bunn P. A., Jr., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol. 2001; 19(13)3210–3218
   PubMed Web of Science ®Google Scholar
• Sandler A. B., Gray R., Brahmer J., et al. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. Part I of II. J. Clin. Oncol. 2005; 23: 4, (Suppl. 16S), 2005 ASCO Annual Meeting Proceedings
   Google Scholar
• Soria J., Haddad V., Olaussen K. A., et al. Immunohistochemical staining of the Excision Repair Cross-Complementing 1 (ERCC1) protein as predictor for benefit of adjuvant chemotherapy (CT) in the International Lung Cancer Trial (IALT). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I 2006; 24: 7010, (Suppl.18S)
   Google Scholar
• Bepler G., Sharma S., Cantor A., et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J. Clin. Oncol. 2004; 22(10)1878–1885
   PubMed Web of Science ®Google Scholar
• Mountain C. F., McMurtrey M. J., Frazier O. H., Barkley T. H., Valdivieso M. Present status of postoperative adjuvant therapy for lung cancer. The Cancer Bulletin 1980; 32(3)108–112
   Google Scholar
• Feld R., Rubinstein L. V., Weisenberger T. H. Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. J. Clin. Oncol. 1984; 2(12)1352–1358
   PubMed Web of Science ®Google Scholar
• Pairolero P. C., Williams D. E., Bergstralh E. J., Piehler J. M., Bernatz P. E., Payne W. S. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann. Thorac. Surg. 1984; 38(4)331–338
   PubMed Web of Science ®Google Scholar
• Harpole D. H., Jr., Herndon J. E., 2nd, Young W. G., Jr., Wolfe W. G., Sabiston D. C., Jr. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995; 76(5)787–796
   Google Scholar
• Yano T., Yokoyama H., Inoue T., et al. The first site of recurrence after complete resection in non-small-cell carcinoma of the lung. Comparison between pN0 disease and pN2 disease. J. Thorac. Cardiovasc. Surg. 1994; 108(4)680–683
   Google Scholar
• Martini N., Bains M. S., Burt M. E., et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J. Thorac. Cardiovasc. Surg. 1995; 109(1)120–129
   PubMed Web of Science ®Google Scholar
• Cangemi V., Volpino P., D'Andrea N., et al. Local and/or distant recurrences in T1-2/N0-1 non-small cell lung cancer. Eur. J. Cardiothorac. Surg. 1995; 9(9)473–478
   PubMed Web of Science ®Google Scholar
• Al-Kattan K., Sepsas E., Fountain S. W., Townsend E. R. Disease recurrence after resection for stage I lung cancer. Eur. J. Cardiothorac. Surg. 1997; 12(3)380
   PubMed Web of Science ®Google Scholar
• Mineo T. C., Ambrogi V., Corsaro V., Roselli M. Postoperative adjuvant therapy for stage IB non-small-cell lung cancer. Eur. J. Cardiothorac. Surg. 2001; 20(2)378–384
   PubMed Web of Science ®Google Scholar
• Xu G., Rong T., Lin P. Adjuvant chemotherapy following radical surgery for non-small-cell lung cancer: a randomized study on 70 patients. Chin. Med. J. (Engl.) 2000; 113(7)617–620
   PubMed Web of Science ®Google Scholar
• Tada H., Tsuchiya R., Ichinose Y., et al. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer 2004; 43(2)167–173
   PubMed Web of Science ®Google Scholar
• SGACLCA randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan). Eur. J. Surg. Oncol. 1995; 21(1)69–77
   Google Scholar
• Wada H., Hitomi S., Teramatsu T. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer : West Japan Study Group for Lung Cancer Surgery. J. Clin. Oncol. 1996; 14(4)1048–1054
   PubMed Web of Science ®Google Scholar
• Wada H., Miyahara R., Tanaka F., Hitomi S. Postoperative adjuvant chemotherapy with PVM (cisplatin + vindesine + mitomycin C) and UFT (uracil + tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for Lung Cancer Surgery (WJSG). Eur. J. Cardiothorac. Surg. 1999; 15(4)438–443
   Web of Science ®Google Scholar